SpyGlass Pharma
SGP
43 hedge funds and large institutions have $330M invested in SpyGlass Pharma in 2026 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 5 closing their positions.
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
200% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 5
23% more funds holding
Funds holding: 35 → 43 (+8)
31.51% less ownership
Funds ownership: 75.85% → 44.34% (-32%)
50% less capital invested
Capital invested by funds: $655M → $330M (-$326M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.3M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$5.91M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.27M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.18M |
| 5 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$1.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$9.72M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
-$2.57M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.46M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$1.44M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$760K |
SGP Hedge Fund Activity: Q2 2026 in Review
43 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in SpyGlass Pharma (SGP) for Q2 2026, worth a combined $330M — down 50% from $655M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new SGP positions and 5 closed out — a net gain of 15 holders — while 15 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $12.3M. The largest seller was First Light Asset Management, exiting entirely with an estimated $9.72M sold.
- 43 institutional investors held SpyGlass Pharma (SGP) as of Q2 2026, up from 35 in Q1 2026.
- Funds reported $330M of SpyGlass Pharma stock for Q2 2026, down 50% quarter-over-quarter.
- 20 funds opened new SpyGlass Pharma positions in Q2 2026 and 5 closed out, a net change of +15 holders.
- The largest SpyGlass Pharma buyer in Q2 2026 was BlackRock, an estimated $12.3M added.
- The largest SpyGlass Pharma seller in Q2 2026 was First Light Asset Management, an estimated $9.72M sold.
Based on aggregated 13F filings for Q2 2026.